At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
In Brief
A Phase 1 clinical trial evaluating Autologous Hematopoietic Stem Cell Transplantation, Busulfan, and 13 other interventions for Ganglioneuroblastoma and 7 related conditions. Completed, enrolled 150 participants across 123 sites in 4 countries.
Detailed Summary
This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread. Giving chemotherapy to the entire body before a stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy or radiation therapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
Study Details
Timeline
Interventions
Undergo autologous peripheral blood stem cell transplant
Given IV
Given IV
Given IV
Given IV
Given IV
Undergo EBRT
Given SC or IV
Optional correlative studies
Given IV
Given IV
Undergo autologous peripheral blood stem cell transplant
Correlative studies
Given IV
Given IV